Skip to main content
Fig. 1 | BMC Musculoskeletal Disorders

Fig. 1

From: Safety and efficacy of a single intra-articular injection of a novel enhanced protein solution (JTA-004) compared to hylan G-F 20 in symptomatic knee osteoarthritis: a randomized, double-blind, controlled phase II/III study

Fig. 1

Patient disposition. JTA-100/2, group of patients receiving an injection of JTA-004 with 100 μg clonidine and 20 mg hyaluronic acid; JTA-200/2, group of patients receiving an injection of JTA-004 with 200 μg clonidine and 20 mg hyaluronic acid; JTA-200/4, group of patients receiving an injection of JTA-004 with 200 μg clonidine and 40 mg hyaluronic acid; reference group, group of patients receiving an injection of the reference treatment (hylan G-F 20); n, number of patients; SAE, serious adverse event

Back to article page